Table 2.
Trial Cohort | US-CT Agreement Score Pre Contrast | US-CT Agreement Score Post Contrast | |||||||
---|---|---|---|---|---|---|---|---|---|
Conspicuity | Tumor margin | Invasion | Adenopathy | Contrast Dose | Conspicuity | Tumor Margin | Invasion | Adenopathy | |
1 | 5.00 | 3.89 | 4.44 | 3.89 | 0.175 mL/m2 | 5.00 | 4.33 | 4.44 | 4.00 |
2 | 4.22 | 3.00 | 4.44 | 3.89 | 0.200 mL/m2 | 4.55 | 3.44 | 4.44 | 4.11 |
3 | 4.78 | 4.44 | 4.11 | 3.56 | 0.275 mL/m2 | 4.45 | 3.44 | 4.67 | 3.78 |
4 | 5.00 | 3.89 | 3.11 | 4.00 | 0.350 mL/m2 | 4.78 | 4.56 | 4.00 | 4.00 |
Average | 4.75 | 3.81 | 4.03 | 3.83 | Average | 4.69 | 3.95 | 4.39 | 3.97 |
Each parameter was scored on a scale of 1 to 5. The aindividual parameter US-CT agreement score was defined as 5 minus the absolute difference of scores between US and CT. The higher the score, the better the agreement. 5 is the highest score, indicating indentical scores for US and CT (e.g., US = 4 and CT = 4, then US-CT agreement score = 5−|4−4| = 5; 1 is the lowest score, indicating polar opposite scores by US and CT (e.g., US = 5 and CT = 1, then US-CT agreement score = 5−|5−1| = 1).